A Phase 4 interventional study of Solifenacin Succinate and Neuro-Muscular Stimulators (NMS) in Urinary Incontinence, sponsored by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia. Status unknown at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-02.
Sponsored by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Urinary Incontinence with a site in Spain — 12 open to participants now, 13 under way, none of them phase 3. Urinary Incontinence · Spain.
Among the 56 studies in Urinary Incontinence with a site in Spain, this one is the 24th largest by planned enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2018, is one of 4 in phase 4, and was the 25th registered.
986 studies on the registry are indexed under Urinary Incontinence; 183 are open to participants now.
Browse Urinary Incontinence studies →12 of the 56 studies in Urinary Incontinence with a site in Spain are open now. Recruiting first, the newest first:
Universidad de Granada · Sites in Spain
Ages 18–45 · Women only · Healthy volunteers
University of Vic - Central University of Catalonia · Sites in Spain, Lithuania, United Kingdom
Ages 50–100
Fundación Universidad Católica de Valencia San Vicente Mártir · Sites in Spain
Ages 60–80 · Women only · Healthy volunteers
Instituto de Salud Carlos III · Sites in Spain
Healthy volunteers
Universidad Europea de Madrid · Sites in Spain
Ages 18–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 110 Urinary Incontinence studies recruiting now, 61 (55%) set no upper age limit and 35 (32%) stop at 75 or younger; 15 take children under 18; 27 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 9 · Phase 4 4
First in 2001; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 66 across 741 interventional studies indexed under Urinary Incontinence.
Median enrollment 113 across the 46 interventional studies, 156 across the 10 observational. Of the 38 that completed or were terminated, 9 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 56 have an industry lead sponsor. The 10 most frequent:
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia is the lead sponsor of 43 studies on the registry; 10 are open to participants now.
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia has 1 study filed under Urinary Incontinence — fewer than ten, so there is no comparison to draw.
5 of the studies in Urinary Incontinence with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07757633Universidad de GranadaPelvic Floor Muscle Training and Neuromuscular Performance in Women's Rugby | 2026-12 |
| NCT06962345Mucosa Innovations, S.L.Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs. | 2026-12 |
| NCT07710508University of ValenciaDifference in Incontinence Prevalence Between High Impact Athletes, Low Impact Athletes and Sedentary Subjects | 2026-12-31 |
| NCT07906431SERGIO MONTERO NAVARRORadiofrequency and Pelvic Floor-Core Exercise for Chronic Low Back Pain in Women With Pelvic Floor Dysfunction | 2027-03-31 |
| NCT06583733University of Vic - Central University of CataloniaKeep On Keep Up Bladder Health: Co-creating and Testing a Self-management Technological Solution for Ageing Well | 2027-08-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Urinary Incontinence with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients will be randomized to receive the usual standard treatment with Solifenacin or treatment based on peripheral unilateral transcutaneous neuromodulation of the posterior tibial nerve .
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Medical device 4 weeks with daily sessions of 30 minutes
Device: Neuro-Muscular Stimulators (NMS)
10 mg tablet daily during 75 days maximum
Drug: Solifenacin Succinate
10 mg tablet daily during 75 days maximum
Also known as: Vesicare
Treatment with T-PTNS will include a first induction period of 4 weeks with daily sessions of 30 minutes duration and performed at each subject's home (Monday through Friday, resting weekends) and a second recall period of 2 additional months, with a session every 4 weeks that will be held at the healthcare center. In total there will be 20 sessions in the induction period and 2 in the recall period
Also known as: T-PTNS
Evaluate whether treatment with T-PTNS is not less than 3 months compared to the current standard pharmacological treatments regarding the episodes of urgency, urinary frequency, incontinence and nocturia, all measured with the 3-day voiding diary
3- day voiding diary
Time frame: 12 weeks
Plan to share: No
No publications or documents are linked to this record.
Started May 2018 (actual). Primary completion is estimated for Mar 2019, 10 months after the start.
Of 17 phase 4 interventional studies under Urinary Incontinence, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia